Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19684181rdf:typepubmed:Citationlld:pubmed
pubmed-article:19684181lifeskim:mentionsumls-concept:C0024501lld:lifeskim
pubmed-article:19684181lifeskim:mentionsumls-concept:C0034802lld:lifeskim
pubmed-article:19684181lifeskim:mentionsumls-concept:C0228174lld:lifeskim
pubmed-article:19684181lifeskim:mentionsumls-concept:C1801960lld:lifeskim
pubmed-article:19684181lifeskim:mentionsumls-concept:C0003009lld:lifeskim
pubmed-article:19684181lifeskim:mentionsumls-concept:C0040624lld:lifeskim
pubmed-article:19684181lifeskim:mentionsumls-concept:C1366765lld:lifeskim
pubmed-article:19684181lifeskim:mentionsumls-concept:C0035028lld:lifeskim
pubmed-article:19684181lifeskim:mentionsumls-concept:C0721534lld:lifeskim
pubmed-article:19684181pubmed:issue4lld:pubmed
pubmed-article:19684181pubmed:dateCreated2009-9-25lld:pubmed
pubmed-article:19684181pubmed:abstractTextThis study identified, on the integrative level, two components of the ANG II signaling pathway that lay downstream from the ANG II type 1 (AT(1)) receptor and are critically involved in maintaining vascular relaxation in cerebral resistance arteries. In these experiments, the relaxation of isolated middle cerebral arteries (MCA) in response to ACh (10(-9)-10(-5) M), iloprost (10(-16)-10(-11) g/ml), and reduced PO(2) was lost and the ratio of phospho-ERK/ERK1/2 was significantly reduced in aortas of male Sprague-Dawley rats fed a high-salt (HS; 4% NaCl) diet to suppress plasma ANG II levels. In salt-fed rats, relaxation of MCA in response to these vasodilator stimuli was restored by chronic (3 days) intravenous infusion of either ANG II (5 ngxkg(-1)xmin(-1)) or epidermal growth factor (EGF; 2 microg/h). The protective effect of ANG II infusion to restore vascular relaxation was eliminated by coinfusion of either the EGF receptor kinase inhibitor AG-1478 (20 microg/h), the ERK1/2 inhibitor PD-98059 (10 microg/h), or the protein synthesis inhibitor cycloheximide (5 microg/h). In rats fed a low-salt (0.4% NaCl) diet, MCA relaxation in response to ACh, reduced PO(2), and iloprost was eliminated by intravenous infusion of AG-1478, PD-98059, or cycloheximide. In ANG II-infused rats fed HS diet, and in rats fed LS diet, vasodilator responses to reduced PO(2) and iloprost were unaffected by the p38 MAP kinase inhibitor SB-203580 and the phosphatidylinositol 3-kinase inhibitor wortmannin. These findings indicate that maintenance of normal vascular relaxation mechanisms by ANG II in rat MCA requires activation of the EGF receptor kinase and ERK1/2.lld:pubmed
pubmed-article:19684181pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:languageenglld:pubmed
pubmed-article:19684181pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:citationSubsetIMlld:pubmed
pubmed-article:19684181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19684181pubmed:statusMEDLINElld:pubmed
pubmed-article:19684181pubmed:monthOctlld:pubmed
pubmed-article:19684181pubmed:issn1522-1539lld:pubmed
pubmed-article:19684181pubmed:authorpubmed-author:LombardJulian...lld:pubmed
pubmed-article:19684181pubmed:authorpubmed-author:McEwenScott...lld:pubmed
pubmed-article:19684181pubmed:authorpubmed-author:BalusSarah...lld:pubmed
pubmed-article:19684181pubmed:authorpubmed-author:DurandMatthew...lld:pubmed
pubmed-article:19684181pubmed:issnTypeElectroniclld:pubmed
pubmed-article:19684181pubmed:volume297lld:pubmed
pubmed-article:19684181pubmed:ownerNLMlld:pubmed
pubmed-article:19684181pubmed:authorsCompleteYlld:pubmed
pubmed-article:19684181pubmed:paginationH1296-303lld:pubmed
pubmed-article:19684181pubmed:dateRevised2010-10-4lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:meshHeadingpubmed-meshheading:19684181...lld:pubmed
pubmed-article:19684181pubmed:year2009lld:pubmed
pubmed-article:19684181pubmed:articleTitleAngiotensin II maintains cerebral vascular relaxation via EGF receptor transactivation and ERK1/2.lld:pubmed
pubmed-article:19684181pubmed:affiliationDepartment of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA.lld:pubmed
pubmed-article:19684181pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19684181pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
entrez-gene:24329entrezgene:pubmedpubmed-article:19684181lld:entrezgene
entrez-gene:50689entrezgene:pubmedpubmed-article:19684181lld:entrezgene
entrez-gene:116590entrezgene:pubmedpubmed-article:19684181lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19684181lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19684181lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:19684181lld:entrezgene